On 17 November 2026 the US Food and Drug Administration announced the Global Reliance Disclosure Program (GRDP), under which companies can request minimally redacted FDA approval packages, including the agency’s scientific and regulatory assessments, and pass them to regulators outside the United States. The program is open now for certain PEPFAR tentative approvals and is planned to widen in January 2027, which matters to drug developers, global-health research groups and the research offices that support them.
What happened
In a press announcement dated 17 November 2026, FDA said the GRDP lets it share approval packages with sponsors with only minimal non-public information removed. The packages include the agency’s detailed scientific review and regulatory rationale. The sponsor can then give the package to a foreign regulatory authority that is assessing a marketing application. FDA says the foreign authority can rely on FDA’s science-based review instead of repeating a full evaluation, while keeping control of its own regulatory decision.
According to the announcement, the program began on 30 October 2026 with a PEPFAR tentative approval for lenacapavir, an HIV prevention and treatment drug. FDA Deputy Commissioner Grace Graham described the agency as the global gold standard, and Mark Abdoo, FDA’s Associate Commissioner for Global Policy and Strategy, said that FDA’s leadership is most effective when it is collaborative.
Key details
| Item | What FDA states |
|---|---|
| What is shared | Minimally redacted approval package, including FDA’s scientific and regulatory assessments |
| Who receives it | The applicant, who may pass it to a foreign regulatory authority supporting a marketing application |
| Eligible now | PEPFAR tentative approvals; tentatively approved ANDA products are excluded |
| Request window | Within 10 calendar days of approval; the applicant confirms the package is going to a foreign regulator |
| How applicants learn the details | Eligible applicants receive information in FDA approval letters; FDA intends to provide packages on an expedited basis |
| January 2027 | Planned expansion to novel drugs and biologics: new molecular entity NDAs and 351(a) BLAs |
| Early 2027 | Planned pathway to request packages for drugs and biologics already on the market |
| Other purposes | Not handled under the GRDP; FDA directs these to a Freedom of Information Act request |
The last row is the practical boundary. The GRDP is a route to a foreign regulator, not a general release of review documents. Anyone who wants the records for another reason, such as academic analysis of a review, still uses the existing disclosure route, described in the CASRAI entry on the FDA FOIA request.
Background and context
Regulatory reliance is the practice of one regulator using another regulator’s work when it can, so that national effort goes to what the World Health Organization calls value-added regulatory activities. WHO published its Good Reliance Practices guidance on 29 April 2021 to make regulation more efficient and speed access to quality-assured, effective and safe medical products. The guidance covers medicines, vaccines, blood and blood products, and medical devices including in vitro diagnostics, and it draws on Pan American Health Organization recommendations and a 2018 to 2019 survey of regulators.
The new FDA program supplies the document that makes reliance workable in practice. A foreign regulator that wants to lean on an FDA review needs the review itself. The GRDP sets up a defined process, with a stated request window, for sponsors to obtain a minimally redacted package and hand it to that regulator.
The first product in the program sits in the global-health pipeline. A report dated 2 November 2026 on FDA’s tentative approval of a first generic injectable lenacapavir for HIV prevention, issued by Unitaid and made by Dr. Reddy’s Laboratories, says such an approval could support national regulatory approvals and speed introduction in the 120 low- and middle-income countries covered by Gilead’s voluntary licensing program. That article does not describe the GRDP, so the two developments are related by subject, not by any stated link.
Reaction
The law-firm bulletin Ermer Suter’s Tuesday Report of 17 November 2026 carried FDA’s description of the GRDP as a landmark initiative that may accelerate patient access to innovative therapies throughout the world. Korean trade outlet Medipana reported on 18 November 2026 that FDA expects the program to reduce duplicative reviews and narrow the gap between US and overseas approval dates, with particular benefit for countries that have limited review staff and capacity. The outlet also noted that the program may affect global pharmaceutical companies’ overseas approval strategies, and that how Korea’s Ministry of Food and Drug Safety uses the materials will depend on its own systems and procedures. FDA did not specify Korean participation.
What it means for researchers, universities and research offices
Most of the effect lands on sponsors, but academic and non-profit developers are sponsors too. Several concrete points follow from FDA’s text.
- Plan for the 10-day window. A university or institute that holds an application subject to a PEPFAR tentative approval, or later a novel drug or biologic approval, should decide before approval who will submit the request and who will confirm the foreign regulator and marketing application.
- Align the foreign filing sequence. The package is meant for a regulator assessing a marketing application. Teams building global-health programs, including multinational trials and licensing deals, can ask which regulators they intend to file with and when, so the FDA package arrives while those reviews are open. The pathway for novel drugs and biologics is planned for January 2027, so submissions expected to be approved after that date are the ones to plan around. The general US route is described in the CASRAI guides to the FDA drug approval process and the new drug application, and the biologics route in FDA approval for gene therapy.
- Keep reliance in the contract. Licensing and sponsor agreements that split regulatory responsibilities between a university, a licensee and a manufacturer should say who holds the application and who may request and transmit the package.
- Use the right channel. A request made for research, journalism or any purpose other than supporting a foreign marketing application goes through FOIA, not the GRDP.
- Know the foreign side. Reliance does not mean automatic approval. Other regulators decide on their own terms, and some already run reliance routes, such as the one described in the CASRAI guide to Egypt’s clinical trial approval pathway.
What happens next
FDA states that eligible applicants will be told how to take part in their approval letters. It intends to expand the program in January 2027 to all novel drugs and biologics (NME NDAs and 351(a) BLAs) and to introduce, in early 2027, a request pathway for products that are already on the market. Until the expansion, the program remains limited to PEPFAR tentative approvals, and tentatively approved ANDA products are outside it.
Sources
- US Food and Drug Administration, “FDA launches Global Reliance Disclosure Program to expand patient access to medicines worldwide”, 17 November 2026
- Ermer Suter, Tuesday Report, 17 November 2026
- Medipana News, 18 November 2026 (Korean)
- Managed Healthcare Executive, FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries, 2 November 2026
- World Health Organization, new guidance to promote strong, efficient and sustainable regulatory systems, 29 April 2021







